Bond Teva Pharmaceutical Industries 5.125% ( US88167AAQ40 ) in USD

Teva Pharmaceutical Industries

100.99 % ▼

Israel

US88167AAQ40 ( in USD )

5.125% per year ( payment 2 times a year)

05/09/2029

88167AAQ4

BB+ ( Non-investment grade speculative )

Ba1 ( Non-investment grade speculative )

11/09/2026 ( In 5 days )

Teva Pharmaceutical Industries is a global pharmaceutical company specializing in generic and specialty medications, with a focus on central nervous system disorders, respiratory diseases, oncology, and women's health.

This financial article provides an overview of a specific debt instrument issued by Teva Pharmaceutical Industries, a global pharmaceutical leader headquartered in Israel, widely recognized as one of the world's largest manufacturers of generic drugs alongside a significant portfolio of specialty medicines. Identified by ISIN US88167AAQ40 and CUSIP 88167AAQ4, this bond, originating from Israel, is currently quoted on the market at 98.8525% of its face value and is denominated in USD. It carries a fixed annual interest rate of 5.125%, with interest payments disbursed semi-annually (frequency 2), and is set to mature on September 5, 2029. The bond's credit risk profile is evaluated by major rating agencies, holding a BB rating from Standard & Poor's and a Ba1 rating from Moody's.

Date	Clean price
03/09/2026	100.99%
01/02/2026	101.36%
11/05/2025	100.47%
09/10/2025	101.14%
07/17/2025	98.85%
05/16/2025	98.02%
02/28/2025	98.74%
01/10/2025	98.87%
11/12/2024	97.70%
09/26/2024	99.25%
09/15/2024	98.66%
08/07/2024	100.00%
08/09/2023	95.50%
07/16/2023	95.50%
06/22/2023	95.50%
05/29/2023	95.50%
05/05/2023	95.50%
04/11/2023	95.50%
03/18/2023	95.50%
02/23/2023	95.50%
01/31/2023	95.50%
01/08/2023	95.50%
12/16/2022	95.50%
11/23/2022	95.50%
10/31/2022	95.50%
10/10/2022	95.50%
09/19/2022	95.50%
08/29/2022	95.50%
08/08/2022	95.50%
07/18/2022	95.50%
06/27/2022	95.50%
06/06/2022	95.50%
05/16/2022	95.50%
04/25/2022	95.50%
04/04/2022	95.50%